AAAAAA

   
Results: 1-9 |
Results: 9
Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumors of different sizes
Authors: Landuyt, W Theys, J Nuyts, S Drijkoningen, M Fowler, J Reijnders, A Liekens, S Neyts, J de Bruijn, E Anne, J Lambin, P
Citation: W. Landuyt et al., Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumors of different sizes, CANCER INV, 19(1), 2001, pp. 35-40
Potent inhibition of hemangiosarcoma development in mice by cidofovir
Authors: Liekens, S Verbeken, E De Clercq, E Neyts, J
Citation: S. Liekens et al., Potent inhibition of hemangiosarcoma development in mice by cidofovir, INT J CANC, 92(2), 2001, pp. 161-167
Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir
Authors: Liekens, S Neyts, J De Clercq, E Verbeken, E Ribatti, D Presta, M
Citation: S. Liekens et al., Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir, CANCER RES, 61(13), 2001, pp. 5057-5064
Amino-terminal truncation of CXCR3 agonists impairs receptor signaling andlymphocyte chemotaxis, while preserving antiangiogenic properties
Authors: Proost, P Schutyser, E Menten, P Struyf, S Wuyts, A Opdenakker, G Detheux, M Parmentier, M Durinx, C Lambeir, AM Neyts, J Liekens, S Maudgal, PC Billiau, A Van Damme, J
Citation: P. Proost et al., Amino-terminal truncation of CXCR3 agonists impairs receptor signaling andlymphocyte chemotaxis, while preserving antiangiogenic properties, BLOOD, 98(13), 2001, pp. 3554-3561
Angiogenesis: regulators and clinical applications
Authors: Liekens, S De Clercq, E Neyts, J
Citation: S. Liekens et al., Angiogenesis: regulators and clinical applications, BIOCH PHARM, 61(3), 2001, pp. 253-270
Inhibition of angiogenesis by blockers of volume-regulated anion channels
Authors: Manolopoulos, VG Liekens, S Koolwijk, P Voets, T Peters, E Droogmans, G Lelkes, PI De Clercq, E Nilius, B
Citation: Vg. Manolopoulos et al., Inhibition of angiogenesis by blockers of volume-regulated anion channels, GEN PH-VASC, 34(2), 2000, pp. 107-116
Antitumor potential of acyclic nucleoside phosphonates
Authors: De Clercq, E Andrei, G Balzarini, J Hatse, S Liekens, S Naesens, L Neyts, J Snoeck, R
Citation: E. De Clercq et al., Antitumor potential of acyclic nucleoside phosphonates, NUCLEOS NUC, 18(4-5), 1999, pp. 759-771
Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds
Authors: Liekens, S Leali, D Neyts, J Esnouf, R Rusnati, M Dell'Era, P Maudgal, PC De Clercq, E Presta, M
Citation: S. Liekens et al., Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds, MOLEC PHARM, 56(1), 1999, pp. 204-213
A novel animal model for hemangiomas: Inhibition of hemangioma developmentby the angiogenesis inhibitor TNP-470
Authors: Liekens, S Verbeken, E Vandeputte, M De Clercq, E Neyts, J
Citation: S. Liekens et al., A novel animal model for hemangiomas: Inhibition of hemangioma developmentby the angiogenesis inhibitor TNP-470, CANCER RES, 59(10), 1999, pp. 2376-2383
Risultati: 1-9 |